PPARG and fatty liver disease: Previous studies have reported the positive effects of the use of PPAR-γ agonists, e.g. thiazolidinediones, in improving blood glucose, lipids profile, and liver enzymes, and reducing steatosis and inflammation in patients with fatty liver [80, 81].